 |
Corporate News
21-Feb-25
|
|
|
|
|
|
|
|
|
|
|
|
Lupin receives EIR for its Somerset facility
|
|
|
|
|
|
|
|
Lupin announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its manufacturing facility in Somerset, New Jersey, for the inspection conducted from 27 January to 31 January 2025.
“We are very pleased to have received the EIR for our Somerset facility. This milestone underscores our commitment to upholding the highest standards of quality and compliance, solidifying our position as a
leading pharmaceutical manufacturer,” said Nilesh Gupta, Managing Director, Lupin.
|
|
|
|
Previous News |
Lupin rallies after receiving USFDA nod for Tolvaptan tablets
(
Hot Pursuit
-
24-Apr-25
11:40
)
|
|
|
Lupin receives USFDA approval for Tolvaptan Tablets
(
Corporate News
-
24-Apr-25
11:06
)
|
|
|
Lupin gets EIR from USFDA for Nagpur facility
(
Hot Pursuit
-
17-Apr-25
15:00
)
|
|
|
Nanomi wins prestigious CMO Award for Life Science Leadership in Drug Delivery
(
Corporate News
-
21-Mar-25
19:12
)
|
|
|
Lupin allots 24,101 equity shares under ESOP
(
Corporate News
-
21-Mar-25
16:10
)
|
|
|
Lupin receives USFDA tentative approval for Amifampridine Tablets
(
Corporate News
-
17-Mar-25
13:36
)
|
|
|
Lupin gains after getting tentative USFDA approval for Amifampridine tablets 10 mg
(
Hot Pursuit
-
17-Mar-25
10:44
)
|
|
|
Lupin launches Rivaroxaban drug in US
(
Hot Pursuit
-
10-Mar-25
10:02
)
|
|
|
Lupin launches Rivaroxaban Tablets USP, 2.5 mg in the US
(
Corporate News
-
07-Mar-25
16:43
)
|
|
|
Lupin Ltd spurts 0.59%, up for five straight sessions
(
Hot Pursuit
-
06-Mar-25
13:00
)
|
|
|
Lupin allots 59,940 equity shares under ESOP
(
Corporate News
-
27-Feb-25
12:40
)
|
|
|
|
|
|
Other Stories |
|
|
|
|
|
|
|
|
|
|
|
|
|